The FDA declined to approve one of biotech’s most closely watched cancer drugs
MarketWatch.com - Top Stories
16 lis 2026, 13:07Marketwatch
1 min read
The FDA declined to approve one of biotech's most closely watched cancer drugs, Summit Therapeutics' lung-cancer treatment.
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Related
Article written by AI
Z.ai GLM-4.5-FlashFree